This document summarizes the neurological implications of von Hippel-Lindau disease. It is an autosomal dominant genetic disorder caused by mutations in the VHL tumor suppressor gene. Patients with VHL frequently develop benign tumors called hemangioblastomas in the brain and spinal cord. While these tumors are non-cancerous, they can cause neurological problems due to their location and mass effect. Younger patients and those with more tumors have worse outcomes and faster tumor progression. Regular screening and surgical removal of tumors can help prevent disability. However, hemangioblastomas remain the most common cause of morbidity and reduced life expectancy in patients with VHL disease.
Primary brain tumours are a diverse group of neoplasm arising from different cells of the central nervous system.
It accounts for about 2% of all cancers with an overall annual incidence of 22 per 1,00,000 population.
Most common brain tumour in adults is Brain Metastasis.
Track 6. Technological innovations in biomedical training and practice
Authors: Jesús M Gonçalves, M J Sanchez-Ledesma, P Ruisoto, M Jaramillo, J J Jimenez and J A Juanes
Primary brain tumours are a diverse group of neoplasm arising from different cells of the central nervous system.
It accounts for about 2% of all cancers with an overall annual incidence of 22 per 1,00,000 population.
Most common brain tumour in adults is Brain Metastasis.
Track 6. Technological innovations in biomedical training and practice
Authors: Jesús M Gonçalves, M J Sanchez-Ledesma, P Ruisoto, M Jaramillo, J J Jimenez and J A Juanes
It is believed that HERVs are the result of ancient viral infections. A number of HERVs have maintained some functionality and still contain intact open reading frames (ORF’s) which code for fully functional proteins. HERV-W is one of these endogenous retroviruses. Over the last few years several research projects have suggested that HERV-W may be involved with multiple sclerosis, bipolar disorder, schizophrenia, autism, and various tumors. The presence of HERV-W RNAs, proteins, and virions has been detected in association with these diseases. This power point presentation was created to be used in conjunction with the associated paper.
The views expressed in the presentations are that of the author and do not necessarily reflect the views of the Government of Canada. Presentations are shared in the original format received from the presenter.
Presentations given at the Conference to Develop a Federal Framework on Lyme Disease are the property of the author, unless otherwise cited. If you reference the author's work, you must give the author credit by naming the author and their work as well as the place and date it was presented.
For more information, contact the Lyme Disease Conference Secretariat at maladie_lyme_disease@phac-aspc.gc.ca
Since the mid twentieth century, psychologists, psychiatrists, and neuroscientists have sought to explain mental illness in biological terms. In this talk, we'll discuss the emergence of influential biological models such as the monoamine hypothesis of depression, the rise of neuropsychopharmacology (the prescription and widespread use of medications such Prozac and Zoloft), and the complexity of studying complex conditions like generalized anxiety and schizophrenia in biological terms.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
2. von Hippel–Lindau (VHL) disease
Neoplasia
Autosomal dominant
Germline mutation of the VHL tumor
suppressor gene (NC_000003.12)
located on the short arm of
chromosome 3
1 in 36.000 births
Highly penetrant > 90 % by age 65
years
Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317-1320.
Wait SD, Vortmeyer AO, Lonser RR, et al. Somatic mutations in VHL germline deletion kindred correlate with mild phenotype. Ann Neurol. 2004; 55(2):236-240.
Maher ER, Iselius L, Yates JR, et al. Von Hippel-Lindau disease: a genetic study.J Med Genet. 1991;28(7):443-447.
Neumann HP, Wiestler OD. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet. 1991;337(8749): 1052-1054.
3. Clinical Presentation
• renal cell carcinomas or cysts,
pheochromocytomas, pancreatic
neuroendocrine tumors or cysts,
and benign cystadenomas of the
adnexal organs.
Viscera
• Hemangioblastomas of the retina
and craniospinal axis as well as
endolymphatic sac tumors
(ELSTs).
CNS
The most frequent cause of VHL disease– associated morbidity and mortality is
craniospinal hemangioblas toma development and progression
Neumann HP, Wiestler OD. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet. 1991;337(8749): 1052-1054.
Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003;361 (9374):2059-2067.
Richard S, Campello C, Taillandier L, Parker F, Resche F; French VHL Study Group. Haemangioblastoma of the central nervous system in von Hippel–Lindau disease. J
Intern Med. 1998; 243(6):547-553.
4. Dornbos, D., Kim, H. J., Butman, J. A., & Lonser, R. R. (2018). Review of the neurological implications of von Hippel–Lindau disease. JAMA neurology, 75(5), 620-627.
5. Diagnosis
Clinical criteria
Genetic testing
Imaging
Opthalmologic screening
24-hour urinary catecholamines.
Dornbos, D., Kim, H. J., Butman, J. A., & Lonser, R. R. (2018). Review of the neurological implications of von Hippel–Lindau disease. JAMA neurology, 75(5), 620-627.
Maher ER, Iselius L, Yates JR, et al. Von Hippel-Lindau disease: a genetic study.J Med Genet. 1991;28(7):443-447
6. Clinical Criteria
Family history (+)
• Single tumor
Family history (-)
• 2 CNS hemangioblastomas or
• 1 CNS hemangioblastoma and a
VHL-associated visceral tumor
Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003;361 (9374):2059-2067.
Lamiell JM, Salazar FG, Hsia YE. Von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore). 1989;68(1): 1-29.
Melmon KL, Rosen SW. Lindau’s disease: review of the literature and study of a large kindred. Am J Med. 1964;36:595-617.
7. Hemangioblastoma
Most common tumor associated with VHL
disease
> 80% of VHL patients develop a craniospinal
hemangioblastoma during their lifetime (with
a mean (SD) age of presentation of 33 (10.2)
years)
> 90 % hemangioblastomas are multiple
Cerebellum (45-50%), brainstem (5-10%),
spinal cord (40-45%)
Patients with solitary CNS hemangioblastoma
should undergo craniospinal imaging,
systemic screening, and genetic testing.
Butman JA, Linehan WM, Lonser RR. Neurologic manifestations of von Hippel-Lindau disease.JAMA. 008;300(11):1334-1342.
Wanebo JE, Lonser RR, Glenn GM, Oldfield EH. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease.J
Neurosurg. 03;98(1):82-94.
Feletti A, Anglani M, Scarpa B, et al.Von Hippel-Lindau disease: an evaluation of natural history and functional disability. Neuro Oncol. 2016;18(7):1011-1020.
8. Tumor Burden, Progression, and Development
Symptomatic tumors grow up to 10 times
faster than asymptomatic tumors.
Younger age is associated with new
tumor development in patients with VHL
disease.
Peritumoral cysts proggresive, grow
faster
Cyst growth rate was associated with
younger age, symptom development,
and anatomical location (cerebellar cysts
enlarged fastest)
Dornbos, D., Kim, H. J., Butman, J. A., & Lonser, R. R. (2018). Review of the neurological implications of von Hippel–Lindau disease. JAMA neurology, 75(5), 620-627.
9. Prognosis
Primary cause of mortality in VHL
Neurological disability ismost likely to
occur in the fourth to fifth decades
withmean life expectancies of 67
years for men and 60 years for women
Binderup ML, Jensen AM, Budtz-Jørgensen EBisgaard ML. Survival and causes of death in patients with von Hippel-Lindau disease.J Med Genet. 2017;54(1):11-18.
Feletti A, Anglani M, Scarpa B, et al. Von Hippel-Lindau disease: an evaluation of natural history and functional disability. Neuro Oncol. 2016;18(7):1011-1020
10. Endolymphatic Sac Tumors
3-15 % in VHL
30 % bilateral typical in VHL
VHL germline mutation in 39%
Initial manifestation of VHL disease for
32% of patients.
Location: vestibular aqueduct
Prognosis: good, once hearing loss
occurs, ELST resection is unlikely to
improve hearing
Dornbos, D., Kim, H. J., Butman, J. A., & Lonser, R. R. (2018). Review of the neurological implications of von Hippel–Lindau disease. JAMA neurology, 75(5), 620-627.
11. Radiology
Butman JA, Linehan WM, Lonser RR Neurologic manifestations of von Hippel-Lindau disease.JAMA. 2008;300(11):1334-1342.
Chittiboina P, Lonser RR. Von Hippel–Lindau disease. Handb Clin Neurol. 2015;132:139-156.
12. Chittiboina P, Lonser RR. Von Hippel–Lindau disease. Handb Clin Neurol. 2015;132:139-156.
Butman JA, Linehan WM, Lonser RR Neurologic manifestations of von Hippel-Lindau disease.JAMA. 2008;300(11):1334-1342.
13. Butman JA, Linehan WM, Lonser RR Neurologic manifestations of von Hippel-Lindau disease.JAMA. 2008;300(11):1334-1342.
14. Treatment
Dornbos, D., Kim, H. J., Butman, J. A., & Lonser, R. R. (2018). Review of the neurological implications of von Hippel–Lindau disease. JAMA neurology, 75(5), 620-627.
15. Summary
Benign pathological origin
However, most frequent sources of
morbidity in patients with VHL disease
due to these tumors’ anatomical
location and/or mass effect
Proper surveillance and management
of this disease mitigate potential
neurological deficits and substantially
improve patient quality of life
